← All trials
NCT03621670
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 27, 2018
- Primary completion
- May 29, 2023
- Completion date
- May 29, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 2700
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- GlaxoSmithKlineLead sponsor
- GlaxoSmithKlineStudy director
Drugs studied
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- pneumococcal 13-valent conjugate vaccine
- live attenuated varicella vaccine
- measles, mumps, and rubella vaccine
- haemophilus influenzae type b conjugate vaccine
- human rotavirus, live attenuated
- meningococcal (group B) vaccine
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.